BioSpace News Archive

During the fourth quarter of 2021, order intake rose 44 percent and net sales 18 percent. Operating loss amounted to SEK -17 M.

Complement Therapeutics Ltd, a preclinical stage University of Manchester spinout, announced the completion of its EUR 5 million seed financing round from BioGeneration Ventures and Forbion, two leading European venture capital firms.

Spago Nanomedical’s annual report for 2021 is from available at the company’s website.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the release of a fully automated GeoMx® RNA protocol on BOND RX research staining systems through an expanded partnership with Leica Biosystems.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2021.

Global pharma major, Lupin Limited (Lupin) announced today changes to its executive team with Dr. Fabrice Egros assuming responsibilities for Global Corporate Development as President, Corporate Development and Growth Markets.

Relmada Therapeutics, Inc. today announced top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company’s lead candidate in Phase 3 development for the treatment major depressive disorder (MDD).

LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter and full year ended December 31, 2021.

BD (Becton, Dickinson and Company) announced that embecta will host a virtual Investor Event on March 7, 2022.

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a panel discussion at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 3:15 pm ET.